Karyopharm Therapeutics Inc

Passed

Class Action Period:
March 02, 2017 - February 22, 2019

Lead Plaintiff Deadline:
September 23, 2019

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Allegations

Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame, you have until September 23, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.